 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Atara Biotherapeutics, Inc. Nasdaq: ATRA, a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will release first quarter 2021 financial results after market close on Tuesday, May 4, 2021. Following the release, the Company will host a live conferen 